Brisalus (Shanghai Brisalus Biomedical) is the full-stack commercialisation partner for Chinese pharma going global — product licensing, regulatory pathway, technology transfer, first supply and commercial launch, handled as one chain. Fees are staged across verifiable milestones, not parked on approval day.
Helping a client finish overseas registration creates value at exactly one moment: approval. If it never comes, so does nothing.
Service stopped at registration and fees sat at the very end. A licensing project typically takes 12–24 months from kick-off to landing: we keep investing with no cash coming back, while the client — paying nothing upfront — has no urgency to move. Projects sit in “in progress”, revenue piles into a single quarter, and one delay wipes out the year.
We extended the scope from registration to licensing, technology transfer, first-supply and commercial maintenance — and moved the fees to five verifiable milestones: signing, submission, approval, first shipment, ongoing sales. The client sees a deliverable at every stage; we see cash at every stage. Momentum and the revenue curve both flatten out.
We match Chinese pharma with overseas markets — but we do not stop at matchmaking. What happens after the deal is signed is our job too.
A portfolio ready for export, but no overseas channel, no registration path in the target country, no one to negotiate the licence, and no partner to actually launch it.
Local sales network and registration capability in place, but no stable product source and no technology-transfer partner — and a pressing need to manufacture locally.
A licensed asset is only worth its market — whether it can be registered where you intend to sell it, and whether anyone there will pay for it. Both questions are far cheaper to answer before the term sheet than after.
Conventional licensing runs on relationships: a dealmaker proposes counterparties from personal knowledge, and the regulatory and reimbursement questions surface later — usually during diligence, sometimes after signature.
We invert that order. Candidates come from continuously maintained matrices rather than from memory, and the registration pathway and reimbursement feasibility are screened as part of the shortlist rather than as a diligence afterthought. The result is a shorter list with a better reason behind each name — and far fewer deals that fail on something that was knowable from the start.
Run in this order for a reason. Each stage either kills a bad idea cheaply or increases confidence in a good one before more money is committed.
The asset, indication, development stage and territory ambition are established, along with what a successful deal would have to look like commercially. A vague brief produces a long shortlist that helps nobody.
Candidates are drawn from the customer matrix and constrained by what the product matrix says about crowding and exclusivity in each target market. Each name arrives with a stated rationale, not just a logo.
Filing routes are assessed against the intended launch sequence, and a gap analysis establishes what the existing data package actually supports — turning a hoped-for timeline into a defensible one.
Comparator expectations, endpoint acceptability and the pricing environment are screened market by market. A product can be approvable and still commercially dead — and that is worth knowing before the valuation is agreed.
Terms, milestones, territory carve-outs and responsibility splits are negotiated, and the agreements are drafted or reviewed so that obligations on both sides are unambiguous.
Filing, technology transfer, supply setup and launch support continue under the same programme plan, so the asset actually reaches the market rather than stalling after signature.
We handle both in-licensing and out-licensing of IP — but never on both sides of the same transaction.
Assets from preclinical through Phase III, matched on therapeutic fit, territory rights and development stage — and screened for whether the registration and reimbursement case holds in the markets you actually want.
Registered and registrable finished products matched to partners with the commercial infrastructure to launch them, with market entry strategy, regulatory compliance and post-deal support handled as part of the programme.
Upfront fees are credited in full against the success fee — the client’s total cost does not rise because of the structure, but the project finally has a reason to move.
Charged monthly by service tier, covering early due diligence, go-global pathway design, and screening and outreach to counterparties. Credited 100% against the later success fee — the client’s effective total cost is unchanged.
Billed independently at each verifiable node — signing, submission, approval, first shipment. Revenue recognition moves forward from “the end of sales” to milestones the client can see.
Set against deal size and licensed scope, with a floor, settled net of fees already paid. Our interest and the client’s are tied to the same outcome: getting the deal done.
Overseas partners used to pay one bundled “product licence fee” and we took a single cut, then left the money flow. Now every service carries its own agreed consideration.
Structuring exclusive or non-exclusive rights, territory split and licence design.
Registration-pathway coordination in the target country, gap lists and submission cadence.
Process and analytical method transfer package, on-site support and Q&A — the T-Bond link.
Coordination and customs clearance from trial batch to first commercial batch.
Pricing strategy, channel onboarding and early-launch support to get product moving.
Cross-timezone, cross-entity coordination with milestone-based delivery and reporting.
Market upkeep, exclusivity renewal and ongoing sales royalty — the long-term relationship.
Each node has a deliverable and a matching billing action — the client knows what they pay for and how far we have got.
We do not take every product. Limited capacity goes to arenas with a real window.
The export window opened by core patent expiry is concentrated and short — the earlier registration starts, the more pricing power and share is left.
Registration pathways, deal structures and valuation models for monoclonal-antibody biosimilars — where our know-how runs deepest.
Mature regulatory pathways and steady demand — well suited to regional bundled licensing and fast scale-up.
No single-market bet — geopolitical and payment risk is spread by country, each with its own landing path.
Three barriers that reinforce each other.
API export, overseas CDMO, licensing and local sales — once the chain is connected, the client receives a one-stop go-global solution rather than a point service. Single-line financial advisers cannot replicate it.
An overseas registration database and counterparty profiling support deal discovery and supply-demand matching, so sourcing is no longer purely relationship-driven.
Focused on GLP-1 and biosimilars, with registration pathways, deal structures and valuation models codified into methodology — which is what lets us price on value.
Start with a feasibility review: market, registration pathway, likely deal structure, and the rough rhythm of investment and return. Scope, deliverables and fees are agreed before work begins.
